Randomised double-blind placebo-controlled trial protocol to evaluate the therapeutic efficacy of lyophilised faecal microbiota capsules amended with next-generation beneficial bacteria in individuals with metabolic dysfunction-associated steatohepatitis

Randomised double-blind placebo-controlled trial protocol to evaluate the therapeutic efficacy of lyophilised faecal microbiota capsules amended with next-generation beneficial bacteria in individuals with metabolic dysfunction-associated steatohepatitis

Background The spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent, affecting 30% of the world’s population, with a significant risk of hepatic and cardiometabolic complications. Different stages of MASLD are accompanied by distinct gut microbial profiles...

Full description

Saved in:
Bibliographic Details
Main Authors: Joanne Verheij, Hilde Herrema, Max Nieuwdorp, Koen Wortelboer, Aldo Grefhorst, Quinten J. J. Augustijn, Pleun de Groen, Jos F ML Seegers, Ismail Sahin Gül, Peter Suenaert, Willem M. de Vos, Adriaan G. Holleboom
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/1/e088290.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/15/1/e088290.full

Similar Items